Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of “Moderate Buy” by Brokerages

Personalis, Inc. (NASDAQ:PSNL) has received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.5714.

PSNL has been the subject of several research analyst reports. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Morgan Stanley raised their price target on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Guggenheim boosted their price objective on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Needham & Company LLC raised their target price on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th.

Insider Transactions at Personalis

In other news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares in the company, valued at $1,334,889.14. The trade was a 16.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. lifted its holdings in shares of Personalis by 33.9% in the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after buying an additional 17,056 shares during the period. Trexquant Investment LP lifted its holdings in Personalis by 455.0% in the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock valued at $432,000 after acquiring an additional 100,804 shares during the period. Royal Bank of Canada lifted its holdings in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after acquiring an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd boosted its position in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after purchasing an additional 33,044 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Price Performance

Personalis stock opened at $8.33 on Friday. Personalis has a 1-year low of $2.83 and a 1-year high of $11.40. The business has a fifty day moving average price of $9.00 and a 200-day moving average price of $7.10. The stock has a market capitalization of $739.70 million, a price-to-earnings ratio of -9.47 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. On average, equities research analysts anticipate that Personalis will post -1.4 earnings per share for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.